Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -37052.06% is 15308% below its 5-year average of -240.48%, near the low end of its 5-year range (-37052.06%–-125.46%).
16576.10% below its 12-month average of -222.19%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2026 (2026-03-31): -209.05%.
RETURN ON EQUITY (ROE)
-37052.06%
RETURN ON EQUITY (ROE) AVG TTM
-222.19%
RETURN ON EQUITY (ROE) AVG 3Y
-225.43%
RETURN ON EQUITY (ROE) AVG 5Y
-240.48%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-16576.10%
CURRENT VS 3Y AVG
-16335.86%
CURRENT VS 5Y AVG
-15307.73%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-37.66%
median of 436 covered companies
CURRENT VS SECTOR MEDIAN
-98285.71%
vs the sector median at left
Adial Pharmaceuticals, Inc.
Market Cap
$11.42M
Return on Equity (ROE)
-37052.06%
TTM Avg
-222.19%
3Y Avg
-225.43%
5Y Avg
-240.48%
Market Cap
$11.41M
Return on Equity (ROE)
-106.87%
TTM Avg
-250.57%
3Y Avg
-230.96%
5Y Avg
-240.83%
Market Cap
$11.21M
Return on Equity (ROE)
-65.18%
TTM Avg
-26.62%
3Y Avg
-94.28%
5Y Avg
-90.35%
Market Cap
$11.01M
Return on Equity (ROE)
-85.82%
TTM Avg
-222.53%
3Y Avg
-140.00%
5Y Avg
-73.12%
Market Cap
$11.94M
Return on Equity (ROE)
-97.47%
TTM Avg
-90.15%
3Y Avg
-205.18%
5Y Avg
-136.35%
Market Cap
$11.95M
Return on Equity (ROE)
N/A
TTM Avg
-43.97%
3Y Avg
-160.70%
5Y Avg
-188.29%
Market Cap
$10.86M
Return on Equity (ROE)
-214.92%
TTM Avg
-46.13%
3Y Avg
-156.76%
5Y Avg
-652.77%
Market Cap
$10.74M
Return on Equity (ROE)
-477.54%
TTM Avg
-207.60%
3Y Avg
64.51%
5Y Avg
-22.91%
Market Cap
$12.46M
Return on Equity (ROE)
N/A
TTM Avg
-162.71%
3Y Avg
-135.96%
5Y Avg
-98.83%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adial Pharmaceuticals, Inc. (ADIL) | $11.42M | -37052.06% | -222.19% | -225.43% | -240.48% |
| Biofrontera Inc. (BFRI)vs › | $11.41M | -106.87% | -250.57% | -230.96% | -240.83% |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.21M | -65.18% | -26.62% | -94.28% | -90.35% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.01M | -85.82% | -222.53% | -140.00% | -73.12% |
| IRIDEX Corporation (IRIX)vs › | $11.94M | -97.47% | -90.15% | -205.18% | -136.35% |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.95M | N/A | -43.97% | -160.70% | -188.29% |
| BioVie Inc. (BIVI)vs › | $10.86M | -214.92% | -46.13% | -156.76% | -652.77% |
| Cerenome, Inc. (CNSY)vs › | $10.74M | -477.54% | -207.60% | 64.51% | -22.91% |
| Cytosorbents Corporation (CTSO)vs › | $12.46M | N/A | -162.71% | -135.96% | -98.83% |
| Caring Brands, Inc. (CABR)vs › | $10.27M | -506.63% | -300.20% | -300.20% | -300.20% |
ROE
-37052.1%
ROA
-198.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | -209.05% |
| 2025-12-31 | -151.18% |
| 2025-09-30 | -178.73% |
| 2025-06-30 | -151.14% |
| 2025-03-31 | -420.83% |
| 2024-12-31 | -324.41% |
| 2024-09-30 | -221.75% |
| 2024-06-30 | -286.20% |
| 2024-03-31 | -142.02% |
| 2023-12-31 | -125.46% |
| 2023-09-30 | -259.47% |
| 2023-06-30 | -234.96% |
| 2023-03-31 | -884.08% |
| 2022-12-31 | -388.57% |
| 2022-09-30 | -290.17% |
| 2022-06-30 | -212.32% |
| 2022-03-31 | -163.42% |
| 2021-12-31 | -553.72% |
| 2021-09-30 | -236.97% |
| 2021-06-30 | -332.98% |
| 2021-03-31 | -239.42% |
| 2020-12-31 | -273.28% |
| 2020-09-30 | -133.83% |
| 2020-06-30 | -89.42% |
| 2020-03-31 | -147.45% |
| 2019-12-31 | -120.32% |
| 2019-09-30 | -89.37% |
| 2019-06-30 | -141.91% |
| 2019-03-31 | -118.79% |
| 2018-12-31 | -261.89% |
| 2018-09-30 | -218.41% |
